文献速递复苏、休克与脓毒症创伤与烧伤

出血严重程度与血浆相关生存获益:一项院前血浆随机试验结果

Severity of hemorrhage and the survival benefit associated with plasma: Results from a randomized prehospital plasma trial.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论院前血浆的生存获益仅见于24小时内红细胞输注量低于大量输血(<10单位)的患者,其中输注4–7单位者获益最显著(HR 0.33,95%CI 0.14–0.80,P=0.013)。

本研究为前瞻性院前血浆随机试验的预设二次分析,纳入501例有失血性休克风险的患者,其中230例随机接受院前血浆。大量输血定义为24小时内输注红细胞≥10单位,共104例需要大量输血。大量输血组死亡率高于非大量输血组(42% vs 26%,P=0.001)。Kaplan-Meier生存曲线显示非大量输血亚组早期即出现生存获益(log rank P=0.008),而大量输血组无生存获益(log rank P=0.949);Cox回归验证了上述结果。按24小时红细胞输注量四分位分析,输注4–7单位者与30天生存显著独立相关(HR 0.33,95%CI 0.14–0.80,P=0.013)。作者认为院前血浆可能对中等输血需求和死亡风险的患者最有益。

要点

  • 在501例有失血性休克风险的患者中,104例需要大量输血(24小时内红细胞≥10单位),大量输血组死亡率42%,非大量输血组26%(P=0.001)。
  • 院前血浆的生存获益仅见于非大量输血亚组(log rank P=0.008),大量输血组未见生存获益(log rank P=0.949)。
  • 24小时红细胞输注4–7单位的患者,院前血浆与30天生存显著独立相关(HR 0.33,95%CI 0.14–0.80,P=0.013)。
  • 作者认为院前血浆可能对中等输血需求和死亡风险的患者最有益。
  • 证据等级:治疗性证据,Level I。

适用人群与场景

  • 有失血性休克风险的患者,来自前瞻性院前血浆随机试验,共501例纳入本二次分析,其中230例随机至院前血浆组。

诊断标准与关键阈值

  • 大量输血(MT)预先定义为24小时内接受红细胞≥10单位。
  • 24小时红细胞输注量按四分位分组,其中4–7单位组显示与30天生存的独立关联(HR 0.33,95%CI 0.14–0.80,P=0.013)。

研究设计与关键结果

  • 研究类型:前瞻性院前血浆随机试验的预设二次分析;样本量501例,其中230例随机至院前血浆组,104例需要大量输血。
  • 大量输血组死亡率高于非大量输血组(42% vs 26%,P=0.001)。
  • Kaplan-Meier生存曲线:非大量输血亚组早期即出现生存分离(log rank P=0.008),大量输血组无生存获益(log rank P=0.949);Cox回归验证了上述发现。
  • 24小时红细胞输注量四分位分析:输注4–7单位者与30天生存显著独立相关(HR 0.33,95%CI 0.14–0.80,P=0.013)。
  • 结论:院前血浆的生存获益仅在红细胞需求低于大量输血水平的患者中显示;接受4–7单位红细胞者获益最稳健;院前血浆可能对中等输血需求和死亡风险的患者最有益。

证据类型、等级与局限

  • 证据类型:前瞻性随机试验的预设二次分析;原文标注证据等级为治疗性,Level I。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为院前血浆可能对中等输血需求(24小时红细胞4–7单位)和死亡风险的患者最有益。
  • 原文结论指出院前血浆的生存获益仅在红细胞需求低于大量输血水平(24小时内<10单位)的患者中显示,大量输血组未见生存获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent randomized clinical trial evidence demonstrated a survival benefit with the use of prehospital plasma in patients at risk of hemorrhagic shock. We sought to characterize the survival benefit associated with prehospital plasma relative to the blood transfusion volume over the initial 24 hours. We hypothesized that the beneficial effects of prehospital plasma would be most robust in those with higher severity of hemorrhage.

METHODS: We performed a prespecified secondary analysis using data derived from a prospective randomized prehospital plasma trial. Blood component transfusion volumes were recorded over the initial 24 hours. Massive transfusion (MT) was defined a priori as receiving ≥10 units of red cells in 24 hours. We characterized the 30-day survival benefit of prehospital plasma and the need for MT and overall 24-hour red cell transfusion volume utilizing Kaplan-Meier survival analysis and Cox proportional hazard regression.

RESULTS: There were 501 patients included in this analysis with 230 randomized to prehospital plasma with 104 patients requiring MT. Mortality in patients who received MT were higher compared with those that did not (MT vs. NO-MT, 42% vs. 26%, p = 0.001). Kaplan-Meier survival curves demonstrated early separation in the NO-MT subgroup (log rank p = 0.008) with no survival benefit found in the MT group (log rank p = 0.949). Cox regression analysis verified these findings. When 24-hour red cell transfusion was divided into quartiles, there was a significant independent association with 30-day survival in patients who received 4 to 7 units (hazard ratio, 0.33, 95% confidence interval, 0.14-0.80, p = 0.013).

CONCLUSION: The survival benefits of prehospital plasma was demonstrated only in patients with red cell requirements below the transfusion level of MT. Patients who received 4 to 7 units of red cells demonstrated the most robust independent survival benefit attributable to prehospital plasma transfusion. Prehospital plasma may be most beneficial in those patients with moderate transfusion requirements and mortality risk.

LEVEL OF EVIDENCE: Therapeutic, Level I.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Anto VP, Guyette FX, Brown J, et al. Severity of hemorrhage and the survival benefit associated with plasma: Results from a randomized prehospital plasma trial. J Trauma Acute Care Surg. 2020. PMID: 31688793. doi:10.1097/TA.0000000000002530

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。